Arrow International announces Aug. 1 an agreement to supply intra-aortic balloon pumps, balloon catheters and accessories to national healthcare alliances VHA and the University Health System Consortium through group purchasing organization Novation. Separately, Masimo teams with GPO Consorta in a dual-source agreement allowing for "a dramatic expansion in the reach of Masimo technology to new healthcare facilities that previously had only one choice for pulse oximetry." In March, Masimo achieved a $420 mil. legal victory over Tyco/Nellcor, whose hospital contracts were found by a Los Angeles federal court to be exclusive and anticompetitive (1"The Gray Sheet" March 28, 2005, p. 11)...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.
Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
